AzTrials
AzTrials

PeriodontitisPhase 3NCT00327561

Effect of Intensive Periodontal Therapy on Vascular Function

A Phase 3 study testing Intensive periodontal therapy and Community based periodontal therapy in people with Periodontitis, run by Eastman Dental Insitute and Hospital at 2 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The hypothesis of the existence of a causal association between the systemic infectious/inflammatory burden represented by periodontitis and endothelial function assessed by flow mediated dilatation of the brachial artery (FMD) is the subject of the proposed investigation. Read more about this study

Who is it for?
Ages 35 to 60 years
Conditions the study is for
Periodontitis
What is being tested?
Intensive periodontal therapy and Community based periodontal therapy
Type of treatment
Surgery or procedure
How many people
120 participants
Where
2 sitesUnited Kingdom
Study dates
Sep 2003to Mar 2005
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Between the ages of 35 and 60 and in good general health.
  • Ability and willingness to follow study procedures and instructions.
  • Must have read, understood and signed the Informed Consent.
  • Must have generalized, moderate to advanced chronic periodontitis.
  • 40-100 pockets with a PD of > 5 must bleed on probing.
  • Absence of other significant oral infections.

Who cannot join

  • Pregnant or lactating females or females of child bearing potential not using acceptable methods of birth control (hormonal, barriers or abstinence).
  • Patients chronically treated (i.e., two weeks or more) with any vasoactive medication (i.e., antihypertensive) or lipid lowering therapy.
  • Patients who started taking nonsteroidal anti-inflammatory drugs within two months prior to the baseline visit.
  • Diagnosis of uncontrolled metabolic diseases including diabetes, kidney, liver, or cardiovascular diseases.
  • Use of systemic antibiotics in the preceding 3 month.
  • Patients taking steroid medications except for acute topical treatment.
Show all 9Show fewer
  • Patients with active infectious diseases such as hepatitis, HIV, or TB.
  • Patients who require antibiotic pre-medication for the performance of periodontal examination or treatment.
  • Patients who received a course of periodontal treatment within the last 6 months.

Trial locations and contacts

2 sites in 1 country.

United Kingdom2 sites
  • UCL Eastman Dental Institute and Hospital

    London, WC1X 8LD

  • UCL Vascular Biology Laboratory - Great Ormond Street Hospital

    London

Other trials in United Kingdom

About this study

Official title: Effects of Non-Surgical Periodontal Therapy on Endothelial Function A Randomized Controlled Clinical Trial

The hypothesis of the existence of a causal association between the systemic infectious/inflammatory burden represented by periodontitis and endothelial function assessed by flow mediated dilatation of the brachial artery (FMD) is the subject of the proposed investigation.

The objective of this randomized controlled clinical trial is to evaluate the effects of periodontal therapy on endothelial function assessed by Flow mediated dilatation (FMD).

Read more

The rationale for this project is twofold:

  • Establish the extent of acute systemic inflammation and endothelial dysfunction associated with the delivery of subgingival instrumentation for the treatment of chronic periodontitis
  • Establish whether or not improved control of chronic periodontal infections results in improved endothelial function and thus the existence of a causal association between periodontitis and endothelial dysfunction.
Read the detailed description

In the last decade considerable evidence has supported the hypothesis that chronic low-grade infections, periodontitis included, and the inflammatory responses associated with them may play a significant role in the onset of atherosclerosis. An inflammatory alteration of the normal endothelial activity is thought to be one of the mechanisms that may link infection with atherosclerosis. It consists of loss of the normal vasodilation, antiplatelet and antithrombotic properties of the vascular walls and it is frequently called endothelial dysfunction. Impaired endothelium-dependent dilatation, an early functional marker of endothelial dysfunction has been demonstrated in young populations with family history of cardiovascular diseases. In the past 15 years a new non invasive and reproducible technique called Flow mediated dilatation (FMD) has been used to assess endothelial function.

Periodontitis is a chronic infection of the tooth supporting apparatus caused primarily by anaerobic gram negative bacteria organised in a biofilm (commonly known as sub-gingival dental plaque); it leads to inflammatory destruction of the periodontal ligament and alveolar bone and eventually to tooth exfoliation. Periodontitis is highly prevalent in both industrialised and developing countries with 10-15% of the adult population being affected by severe forms of this disease. Recognized risk factors include genetic polymorphisms in inflammatory genes, environmental exposures such as cigarette smoking, and systemic diseases such as diabetes. Local periodontal production of prostaglandins and pro-inflammatory cytokines has been associated with activation of matrix metalloproteinases and eventually to destruction of the periodontal ligament and alveolar bone. It is the primary cause of tooth loss in adult populations and as such leads to long term disability and increased treatment needs.

Local periodontal infections have been associated with a systemic response characterized by increased serum levels of C-reactive protein (CRP), hyper-fibrinogenemia, moderate leukocytosis, as well as increased serum levels of IL-1 and IL-6 when compared with unaffected control populations.

Several epidemiological studies have associated increased levels of acute phase markers with higher risk for cardiovascular atherosclerotic events. Among these markers, C-reactive protein is considered to be one of the most sensitive and probably to be an independent risk factor of atherosclerosis. It is produced by the liver presumably for adaptive or defensive reasons in response to a variety of inflammatory stimuli, including chronic low grade infections.

In a recently completed pilot trial we have been able to establish that treatment of periodontal infections resulted in a significant decrease in serum CRP. In that study, treatment of periodontal infections led to a significant decrease in serum CRP (0.5 mg/L, 95% CI 0.4 to 0.7 mg/L) and IL6 in otherwise healthy individuals affected with severe, generalized periodontitis and indicated that periodontitis contributed to the systemic inflammatory responses.

The treatment associated decrease in systemic inflammatory markers observed in this study supports the hypothesis that periodontal infections, along with chronic low grade infections in other body districts, contribute to the inflammatory burden of an individual and may play a contributory etiologic role in atherosclerosis. It remains to be established whether or not the observed improvements in serum CRP have an impact on functional vascular parameters and endothelial function/dysfunction.

The relationship between periodontal treatment and changes in serum CRP is likely to be bimodal: an increase associated with the delivery of the standard subgingival instrumentation and the associated bacteremia and tissue damage is expected shortly after treatment is delivered.

Preliminary trials from our group aimed at the establishment of the pattern of CRP changes in the first days following delivery of periodontal therapy. The data indicate that serum CRP levels sharply increase after treatment but that values tend to return to baseline levels by one week. This bimodal pattern of changes in serum CRP levels is important since previous investigations have established links between functional vascular parameters such as flow mediated dilatation (FMD) and serum markers of systemic inflammation such as CRP.

Periodontal therapy therefore may lead to an initial improve FMD parameters in subject were periodontitis contributes to systemic inflammation and atherosclerosis. The hypothesis of the existence of a causal association between the systemic infectious/inflammatory burden represented by periodontitis and endothelial function assessed by FMD is the subject of the proposed investigation.

Compare the effects of an intensive periodontal treatment regimen with a community based periodontal care approach in terms of changes in:

  • Flow mediated dilatation of the brachial artery (primary outcome)
  • Acute phase response in serum (CRP, IL-6,fibrinogen)
  • Clinical periodontal parameters: PI, BoP, PPD (CAL)
  • Presence of periodontal pathogens in the periodontal pockets before and after treatment
  • Patient perception and adverse events associated with the treatment experience This will be a randomized controlled clinical trial. Its design will be parallel arm, single blind; outcomes will be evaluated over a 6 months period and will include approximately 120 subjects. Two interventions will be compared: test treatment will be an intensive regimen of periodontal therapy consisting of oral hygiene instructions and subgingival debridement delivered at two appointments over a 24 hour period; control treatment will consist of a community based periodontal care approach consisting of supragingival removal of deposits delivered at two appointments over a 24 hour period. The control group will receive the intensive regimen upon completion of the study or upon evidence that periodontitis is progressing. Subjects with moderate to severe periodontitis will be recruited among those referred for care to the Periodontal Clinic of the Eastman Dental Hospital. The primary outcome measure of this study will be changes in Flow Mediated Dilatation (FMD) of the brachial artery. Secondary outcomes will include changes in serum CRP and plasma fibrinogen. Periodontal, microbiological and subjective outcomes will be evaluated as control outcomes. The primary and the secondary outcome variables will be evaluated before treatment and at 1 day, 7 days, 2 months and 6 months following completion of treatment. Subjects will be randomized to treatment stratifying for smoking status by a study registrar. Treatment allocation will be concealed to study personnel by using opaque envelopes and to the examiner by making treatment records unavailable. All laboratory and FMD analyses will be performed by unrelated study personnel blind with respect to treatment allocation or stage of progression of the trial. Intent to treat analyses will be performed by a statistician blind with respect to treatment allocation.
Conditions
Periodontitis
Being tested
Intensive periodontal therapy, Community based periodontal therapy
Keywords
Inflammation, Periodontitis, Endothelial function, Atherosclerosis, Controlled trial
Medical subject headings
Periodontitis, Inflammation, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intensive periodontal therapyProcedure or surgery

  • Community based periodontal therapyProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Flow mediated dilatation of the brachial artery

Secondary outcomes (1)
  1. Serum inflammatory and endothelial function markers

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2006 (estimated)
  2. Study startSep 2003
  3. Study completionMar 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
120 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00327561
Sponsor's protocol ID
UCLH03/E007
Status last verified
Mar 2005
First submitted
16 May 2006
Last updated
18 May 2006
Results posted
No

Publications

  • D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial. Am Heart J. 2006 May;151(5):977-84. doi: 10.1016/j.ahj.2005.06.018.

    PubMed 16644317
  • D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res. 2005 Mar;84(3):269-73. doi: 10.1177/154405910508400312.

    PubMed 15723869
  • D'Aiuto F, Parkar M, Andreou G, Suvan J, Brett PM, Ready D, Tonetti MS. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res. 2004 Feb;83(2):156-60. doi: 10.1177/154405910408300214.

    PubMed 14742655
  • D'Aiuto F, Tonetti MS. Contribution of periodontal therapy on individual cardiovascular risk assessment. Arch Intern Med. 2005 Sep 12;165(16):1920-1. doi: 10.1001/archinte.165.16.1920. No abstract available.

    PubMed 16157839
  • D'Aiuto F, Parkar M, Brett PM, Ready D, Tonetti MS. Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine. 2004 Oct 7;28(1):29-34. doi: 10.1016/j.cyto.2004.06.005.

    PubMed 15341923
  • D'Aiuto F, Parkar M, Tonetti MS. Periodontal therapy: a novel acute inflammatory model. Inflamm Res. 2005 Oct;54(10):412-4. doi: 10.1007/s00011-005-1375-4.

    PubMed 16283108
  • D'Aiuto F, Parkar M, Andreou G, Brett PM, Ready D, Tonetti MS. Periodontitis and atherogenesis: causal association or simple coincidence? J Clin Periodontol. 2004 May;31(5):402-11. doi: 10.1111/j.1600-051X.2004.00580.x.

    PubMed 15086624

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Intensive periodontal therapy and Community based periodontal therapy in people with Periodontitis, run by Eastman Dental Insitute and Hospital at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2006. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Flow mediated dilatation of the brachial artery. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00327561, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2006.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in